URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
UroGen Pharma Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$34.15−0.41 (-1.19%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
86.8%
42M of 49M shares
Institutional holders
189
40 new, 21 sold out
Net institutional buying
-4M
In Q2 2026
Insider trades, 12 months
0 buys · 14 sales
Net sold $4.69M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roderick Wong, M.D | 4,930,204 | 9.99% | 13G (passive) amendment | Sep 30, 2024 |
| The Toronto-Dominion Bank | 3,269,957 | 6.70% | 13G (passive) amendment | Jun 30, 2026 |
| RA Capital Management, L.P. | 3,206,271 | 7.00% | 13G (passive) amendment | Mar 31, 2025 |
| Adage Capital Management, L.P. | 2,928,086 | 6.94% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 2,519,771 | 5.20% | 13G (passive) | Mar 31, 2026 |
| Morgan Stanley | 2,488,299 | 5.40% | 13G (passive) | Jun 30, 2025 |
| Paradigm BioCapital Advisors LP | 2,332,066 | 5.00% | 13G (passive) | Aug 5, 2025 |
| Soleus GP, LLC | 2,325,000 | 5.00% | 13G (passive) | Jun 13, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of URGN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rtw Investments, LP | 4,543,895 | 9.30% | $167.22M | – | 1.43% |
| BlackRock, Inc. | 3,201,461 | 6.55% | $117.81M | +355,894 | 0.00% |
| Morgan Stanley | 2,576,363 | 5.27% | $94.81M | +16,325 | 0.01% |
| Kynam Capital Management, LP | 2,434,207 | 4.98% | $89.58M | +186,814 | 4.95% |
| Jefferies Financial Group Inc. | 2,199,652 | 4.50% | $80.95M | – | 0.53% |
| SG Americas Securities, LLC | 2,052,906 | 4.20% | $75.55K | +395,060 | 0.04% |
| American Century Companies Inc | 1,685,719 | 3.45% | $62.03M | +48,149 | 0.03% |
| Acorn Capital Advisors, LLC | 1,673,420 | 3.42% | $61.58M | – | 16.80% |
| Point72 Asset Management, L.P. | 1,525,549 | 3.12% | $56.14M | New | 0.06% |
| Frontier Capital Management Co LLC | 1,508,547 | 3.09% | $55.51M | +194,435 | 0.52% |
| Opaleye Management Inc. | 1,439,996 | 2.95% | $52.99M | +9,996 | 4.80% |
| Silverarc Capital Management, LLC | 1,301,979 | 2.66% | $47.91M | −201,066 | 4.98% |
| Menora Mivtachim Holdings Ltd. | 1,152,531 | 2.36% | $42.41M | – | 0.17% |
| D. E. Shaw & Co., Inc. | 1,145,819 | 2.34% | $42.17M | +122,660 | 0.02% |
| State Street Corp | 1,003,071 | 2.05% | $36.91M | +128,895 | 0.00% |
| Mpm Bioimpact LLC | 933,415 | 1.91% | $34.35M | −10,388 | 2.09% |
| Soleus Capital Management, L.P. | 829,810 | 1.70% | $30.54M | +102,810 | 1.05% |
| Goldman Sachs Group Inc | 819,834 | 1.68% | $30.17M | +221,306 | 0.00% |
| Migdal Insurance & Financial Holdings Ltd. | 770,909 | 1.58% | $28.37M | – | 0.18% |
| Orbimed Advisors LLC | 676,187 | 1.38% | $24.88M | −199,300 | 0.46% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 189 | 42M | 86.8% | 40 / 61 | 54 / 21 | 5M | 9M |
| Q1 2026 | 173 | 46M | 95.0% | 33 / 52 | 47 / 25 | 11M | 8M |
| Q4 2025 | 167 | 44M | 89.4% | 30 / 53 | 52 / 24 | 9M | 10M |
| Q3 2025 | 161 | 45M | 91.1% | 34 / 48 | 47 / 22 | 12M | 8M |
| Q2 2025 | 150 | 41M | 83.2% | 40 / 46 | 40 / 30 | 16M | 17M |
| Q1 2025 | 140 | 42M | 85.2% | 20 / 46 | 48 / 17 | 10M | 4M |
| Q4 2024 | 138 | 36M | 74.2% | 30 / 42 | 39 / 20 | 10M | 9M |
| Q3 2024 | 128 | 35M | 72.0% | 26 / 50 | 29 / 12 | 7M | 8M |
| Q2 2024 | 115 | 38M | 78.2% | 23 / 55 | 20 / 19 | 13M | 2M |
| Q1 2024 | 112 | 28M | 57.2% | 20 / 32 | 35 / 13 | 7M | 1M |
| Q4 2023 | 105 | 22M | 44.8% | 16 / 50 | 19 / 12 | 5M | 1M |
| Q3 2023 | 101 | 18M | 36.3% | 24 / 35 | 22 / 8 | 7M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of URGN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Small Cap Growth Fund | 874,981 | 1.79% | $33.46M | 0.60% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 206,762 | 0.42% | $5.82M | 0.03% | May 31, 2026 |
| Vanguard Explorer Value Fund | 189,986 | 0.39% | $5.34M | 0.43% | May 31, 2026 |
| Vanguard Health Care Index Fund | 118,284 | 0.24% | $3.33M | 0.02% | May 31, 2026 |
| Clearwater Select Equity Fund | 61,274 | 0.13% | $2.25M | 0.44% | Jun 30, 2026 |
| Tema Oncology ETF | 58,518 | 0.12% | $1.65M | 0.93% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 52,750 | 0.11% | $2.02M | 0.05% | Jul 31, 2026 |
| Amplify BlueStar Israel Technology ETF | 43,319 | 0.09% | $1.59M | 1.33% | Jun 30, 2026 |
| M Capital Appreciation Fund | 36,861 | 0.08% | $1.36M | 0.43% | Jun 30, 2026 |
| Nuveen Equity Index Fund | 34,807 | 0.07% | $1.33M | 0.00% | Jul 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 33,104 | 0.07% | $931.22K | 0.05% | May 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 31,194 | 0.06% | $877.49K | 0.05% | May 31, 2026 |
| Small Cap Index Fund | 21,528 | 0.04% | $792.23K | 0.05% | Jun 30, 2026 |
| Global X Russell 2000 ETF | 20,398 | 0.04% | $780.02K | 0.05% | Jul 31, 2026 |
| Global Small Cap Fund | 17,772 | 0.04% | $499.93K | 0.77% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mark Schoenberg | Chief Medical Officer | 67,849 | 0.14% | Sep 9, 2026 |
| Jason Drew Smith | General Counsel | 53,141 | 0.11% | Sep 9, 2026 |
| Elizabeth A. Barrett | Chief Executive Officer | 313,358 | 0.64% | Feb 19, 2026 |
| Chris Degnan | Chief Financial Officer | 2,280 | 0.00% | Feb 3, 2026 |
| James A. Robinson Jr. | Director | 8,000 | 0.02% | Aug 28, 2026 |
| Daniel George Wildman | Director | 2,000 | 0.00% | Jun 24, 2026 |
| Leana Wen | Director | 2,000 | 0.00% | Jun 24, 2026 |
| Cynthia M. Butitta | Director | 2,000 | 0.00% | Jun 24, 2026 |
| Arie Belldegrun | Director | 408,693 | 0.84% | Jun 24, 2026 |
| Stuart Holden | Director | 2,000 | 0.00% | Jun 24, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark Schoenberg Chief Medical Officer | Sep 8, 2026 | Sale | −871 | $42.92 | $37.38K | 59,882 |
| Jason Drew Smith General Counsel | Sep 8, 2026 | Sale | −1,519 | $42.54 | $64.62K | 53,141 |
| Mark Schoenberg Chief Medical Officer | Sep 7, 2026 | Option exercise | +1,667 | – | – | 60,753 |
| Jason Drew Smith General Counsel | Sep 7, 2026 | Option exercise | +3,334 | – | – | 54,660 |
| James A. Robinson Jr. Director | Aug 26, 2026 | Option exercise | +2,000 | – | – | 8,000 |
| Mark Schoenberg Chief Medical Officer | Aug 20, 2026 | Sale | −60,677 | $47.05 | $2.85M | 59,086 |
| Mark Schoenberg Chief Medical Officer | Jul 9, 2026 | Sale(10b5-1 plan) | −10,000 | $40.00 | $400.00K | 119,763 |
| Mark Schoenberg Chief Medical Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −10,000 | $35.01 | $350.10K | 129,763 |
| Mark Schoenberg Chief Medical Officer | Jun 8, 2026 | Option exercise | +10,000 | – | – | 144,985 |
| Mark Schoenberg Chief Medical Officer | Jun 8, 2026 | Sale | −5,222 | $27.30 | $142.56K | 139,763 |
| James A. Robinson Jr. Director | May 26, 2026 | Option exercise | +2,000 | – | – | 6,000 |
| Mark Schoenberg Chief Medical Officer | May 8, 2026 | Sale(10b5-1 plan) | −10,000 | $30.00 | $300.00K | 134,985 |
| Jason Drew Smith General Counsel | Feb 3, 2026 | Sale | −2,654 | $19.69 | $52.26K | 52,934 |
| Jason Drew Smith General Counsel | Feb 3, 2026 | Sale | −1,608 | $19.69 | $31.66K | 51,326 |
| Jason Drew Smith General Counsel | Feb 3, 2026 | Sale | −3,217 | $19.69 | $63.34K | 55,588 |
| Mark Schoenberg Chief Medical Officer | Feb 3, 2026 | Sale | −1,844 | $19.69 | $36.31K | 150,514 |
| Mark Schoenberg Chief Medical Officer | Feb 3, 2026 | Sale | −3,686 | $19.69 | $72.58K | 144,985 |
| Mark Schoenberg Chief Medical Officer | Feb 3, 2026 | Sale | −1,843 | $19.69 | $36.29K | 148,671 |
| Jason Drew Smith General Counsel | Jan 31, 2026 | Option exercise | +5,500 | – | – | 55,472 |
| Jason Drew Smith General Counsel | Jan 31, 2026 | Option exercise | +6,667 | – | – | 49,972 |
| Jason Drew Smith General Counsel | Jan 31, 2026 | Option exercise | +3,333 | – | – | 58,805 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2026 | Option exercise | +6,666 | – | – | 152,358 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2026 | Option exercise | +3,333 | – | – | 145,692 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2026 | Option exercise | +3,334 | – | – | 142,359 |
| James A. Robinson Jr. Director | Nov 26, 2025 | Option exercise | +2,000 | – | – | 2,000 |
| Cynthia M. Butitta Director | Nov 26, 2025 | Option exercise | +2,000 | – | – | 2,000 |
| Leana Wen Director | Nov 26, 2025 | Option exercise | +2,000 | – | – | 2,000 |
| Daniel George Wildman Director | Nov 26, 2025 | Option exercise | +2,000 | – | – | 2,000 |
| Stuart Holden Director | Nov 26, 2025 | Option exercise | +2,000 | – | – | 2,000 |
| Mark Schoenberg Chief Medical Officer | Nov 19, 2025 | Sale(10b5-1 plan) | −10,000 | $25.00 | $250.00K | 139,025 |
| Chris Degnan Chief Financial Officer | Oct 8, 2025 | Sale | −2,203 | $16.85 | $37.12K | 2,280 |
| Chris Degnan Chief Financial Officer | Oct 8, 2025 | Option exercise | +4,483 | – | – | 4,483 |
| Jason Drew Smith General Counsel | Sep 8, 2025 | Sale | −1,520 | $19.11 | $29.05K | 43,305 |
| Mark Schoenberg Chief Medical Officer | Sep 8, 2025 | Sale | −871 | $19.11 | $16.64K | 149,025 |
| Jason Drew Smith General Counsel | Sep 7, 2025 | Option exercise | +3,333 | – | – | 44,825 |
| Mark Schoenberg Chief Medical Officer | Sep 7, 2025 | Option exercise | +1,667 | – | – | 149,896 |
| Mark Schoenberg Chief Medical Officer | Aug 11, 2025 | Sale | −10,000 | $17.69 | $176.90K | 148,229 |
| Jason Drew Smith General Counsel | Jul 28, 2025 | Option exercise | +16,500 | – | – | 49,014 |
| Jason Drew Smith General Counsel | Jul 28, 2025 | Sale | −7,522 | $19.14 | $143.97K | 41,492 |
| Mark Schoenberg Chief Medical Officer | Jul 28, 2025 | Option exercise | +10,000 | – | – | 163,378 |
| Mark Schoenberg Chief Medical Officer | Jul 28, 2025 | Sale | −5,149 | $19.14 | $98.55K | 158,229 |
| Mark Schoenberg Chief Medical Officer | Jun 9, 2025 | Sale | −5,162 | $7.37 | $38.04K | 153,378 |
| Mark Schoenberg Chief Medical Officer | Jun 8, 2025 | Option exercise | +10,000 | – | – | 158,540 |
| James A. Robinson Jr. Director | Feb 26, 2025 | Option exercise | +2,000 | – | – | 4,000 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2025 | Sale | −1,896 | $11.14 | $21.12K | 148,540 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2025 | Option exercise | +1,334 | – | – | 146,425 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2025 | Sale | −759 | $11.14 | $8.46K | 145,666 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2025 | Option exercise | +3,333 | – | – | 148,999 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2025 | Sale | −1,896 | $11.14 | $21.12K | 147,103 |
| Mark Schoenberg Chief Medical Officer | Jan 31, 2025 | Option exercise | +3,333 | – | – | 150,436 |
| Jason Drew Smith General Counsel | Jan 31, 2025 | Option exercise | +5,500 | – | – | 35,281 |
| Jason Drew Smith General Counsel | Jan 31, 2025 | Sale | −3,354 | $11.14 | $37.36K | 29,781 |
| Jason Drew Smith General Counsel | Jan 31, 2025 | Sale | −1,258 | $11.14 | $14.01K | 26,468 |
| Jason Drew Smith General Counsel | Jan 31, 2025 | Option exercise | +2,500 | – | – | 27,726 |
| Jason Drew Smith General Counsel | Jan 31, 2025 | Option exercise | +6,667 | – | – | 33,135 |
| Jason Drew Smith General Counsel | Jan 31, 2025 | Sale | −2,767 | $11.14 | $30.82K | 32,514 |
| Dong Kim Chief Financial Officer | Sep 9, 2024 | Option exercise | +2,500 | – | – | 37,753 |
| Mark Schoenberg Chief Medical Officer | Sep 9, 2024 | Sale | −859 | $13.08 | $11.24K | 145,091 |
| Mark Schoenberg Chief Medical Officer | Sep 9, 2024 | Option exercise | +1,666 | – | – | 145,950 |
| Jason Drew Smith General Counsel | Sep 9, 2024 | Sale | −1,521 | $13.08 | $19.89K | 25,226 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Degnan Christopher Officer | Oct 9, 2026 | 2,202 | $89.62K | Oct 8, 2026 | Shares issued upon vesting of RSUs |
| Schoenberg Mark Officer | Sep 9, 2026 | 871 | $38.40K | Sep 8, 2026 | Shares issued upon vesting of RSUs |
| Smith Jason Officer | Sep 9, 2026 | 1,519 | $66.97K | Sep 8, 2026 | Shares issued upon vesting of RSUs |
| Mark Schoenberg Officer | Aug 20, 2026 | 60,677 | $2.89M | Aug 20, 2026 | STOCK OPTION EXERCISE |
| Mark Schoenberg Officer | Jul 9, 2026 | 10,000 | $400.01K | Jul 9, 2026 | STOCK OPTION EXERCISE |
| Mark Schoenberg Officer | Jun 22, 2026 | 10,000 | $350.14K | Jun 22, 2026 | STOCK OPTION EXERCISE |
| Mark Schoenberg Officer | Jun 9, 2026 | 5,222 | $140.21K | Jun 8, 2026 | Shares issued upon vesting of RSUs |
| Mark Schoenberg Officer | May 8, 2026 | 10,000 | $300.05K | May 8, 2026 | OPTION EXERCISE |
| Mark Schoenberg Officer | Feb 3, 2026 | 13,333 | $261.46K | Feb 2, 2026 | RSU |
| Mark Schoenberg Officer | Nov 19, 2025 | 10,000 | $250.01K | Nov 19, 2025 | STOCK OPTION EXERCISE |
| Mark Schoenberg Officer | Sep 9, 2025 | 871 | $16.44K | Sep 8, 2025 | RSU |
| Jason Drew Smith Officer | Sep 9, 2025 | 1,520 | $28.70K | Sep 8, 2025 | RSU |
| Mark Schoenberg Officer | Jul 29, 2025 | 5,149 | $97.57K | Jul 28, 2025 | Restricted Stock Units |
| Jason Drew Smith Officer | Jul 29, 2025 | 7,522 | $142.54K | Jul 28, 2025 | Restricted Stock Units |
| Mark Schoenberg Officer | Jun 10, 2025 | 5,162 | $38.04K | Jun 9, 2025 | Restricted Stock Units |